Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites

Details for Australian Patent Application No. 2005313388 (hide)

Owner Solvay Pharmaceuticals B.V.

Inventors Van Hes, Roelof; Tulp, Martinus; Kruse, Cornelis G.; Smid, Pieter

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2005313388

PCT Pub. Number WO2006/061374

Priority 60/633,447 07.12.04 US; 04106361.1 07.12.04 EP

Filing date 6 December 2005

Wipo publication date 15 June 2006

International Classifications

A61K 31/496 (2006.01) - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

Event Publications

5 July 2007 PCT application entered the National Phase

  PCT publication WO2006/061374 Priority application(s): WO2006/061374

3 December 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005313390-Aryloxyethylamine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition

2005313387-Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites